question · intermediate · partly written
How are a dose and a schedule chosen from the PK/PD models?
A first-in-human dose is an animal-derived safety margin; the label dose comes from escalation and exposure-response work, and oncology doses have often needed later correction.
The short answer
A first-in-human dose is a safety margin, not a dose predicted to work. FDA 2005 takes the highest animal dose with no adverse effect, scales it by body surface area and divides by 10; EMA 2017 takes the lowest of several estimates, including the dose expected to give the first biological effect. In patients doses are raised by a rule until toxicity limits them, and later work picks the label dose from exposure and response. 123
Reported, not yet replicated
From animal data to a first human dose more
FDA 2005 (healthy adult volunteers): find the highest dose with no observed adverse effect (NOAEL) in each animal species; convert it to a human equivalent dose by body surface area; take the lowest species result; divide by a default safety factor of 10, which the guidance calls "a historically accepted value"; and lower the start if the dose expected to be pharmacologically active is lower still. The guidance says the surface-area rule rests mainly on 1966 and 1970 work on anticancer drugs, and that body weight to the power 0.75 fits better but surface area is kept because it gives a more conservative start: a safety policy, not a best fit.
EMA 2017 differs. The start is tied to the lowest of estimates from the NOAEL exposure, the pharmacologically active dose and the minimal anticipated biological effect level (MABEL: the dose expected to give the first measurable biological effect, estimated from human-cell data and receptor occupancy). No fixed safety factor is given; protocols state a maximum step between cohorts and sentinel dosing is expected. The reading was of a file headed as the consultation release, so the adopted wording was not compared.
Why MABEL exists: in March 2006 six healthy men each received one dose of the anti-CD28 antibody TGN1412 and all became critically ill within hours; all survived. A proposed reason animals missed it is that CD28 is not expressed on a T-cell subset in the preclinical species.
What real programmes do: in a review of 79 first-in-human antibody studies, median safety factors were 41.5 for NOAEL-based starts (range 3.2 to 1,290) and 10 for MABEL-based; MABEL use rose from 6.3% of studies (1990 to 2007) to 31.6% (2011 to 2013). In an industry survey, for about a third of new molecular entities the maximum tolerated dose, efficacious dose or recommended phase 2 dose was over 100-fold above the MABEL-based start, and a 2024 industry paper says MABEL starts often proved sub-therapeutic. That paper's view is not an established mechanism. 12456789
Reported, not yet replicated
From the first dose to the label dose more
In the 3+3 design three patients receive each dose level: no dose-limiting toxicity (DLT) means go up, one means add three more, two or more means stop and the level below is the maximum tolerated dose (MTD). Model-based designs (the continual reassessment method, and BOIN, which compares the observed DLT rate with fixed boundaries, 0.236 and 0.358 for a 30% target) were proposed to do better, yet 32 of 34 phase I trials in one journal in 2015 used 3+3 or a variant. With 6 patients and 1 DLT the 95% interval for the true toxicity rate is 0.4% to 64.1%, which shows how noisy an MTD is.
The MTD has been the usual registration dose for chemotherapy. FDA's final 2024 guidance (Project Optimus) says targeted drugs often show different dose-response relationships and wider therapeutic indices, so the MTD may be unnecessarily high, and asks for a randomised comparison of more than one dosage (dose plus schedule) before approval. The evidence: of 54 FDA-approved oncology small molecules (2017 to 2023), 28% were approved at the MTD; those labelled at the MTD had the highest median dose-reduction rate (28.0%, against 10.5% for labels below the maximum studied dose); and seven drugs received a postmarketing requirement for dose optimisation. The authors say reporting is not standardised. No source opened shows whether the guidance has changed outcomes. 1011121331415
Reported, not yet replicated
What exposure is aimed at, and how the schedule follows from half-life more
Exposure means concentration over time: peak (Cmax), trough (Cmin, just before the next dose) and area under the curve (AUC). FDA's 2003 exposure-response guidance names these, says long-term effects are often best related to steady-state AUC, and says relating response to concentration across a dosing interval "can provide critical information for choosing a dose and dosing interval". It sets no numeric target. ICH E4 says concentration-response is essential where blood levels define a therapeutic window, and that where the dosing interval is long against the half-life the pharmacodynamic basis of the interval needs attention, because peak and trough responses can differ.
Numeric targets exist only drug by drug. For HIV antivirals a field review says concentrations are now accepted to stay above the protein-binding-adjusted EC90 or EC95 (derived in cell culture) across the interval, and says it is not known to apply to SARS-CoV-2. For imatinib in a randomised phase II, the lowest steady-state trough quartile (below 1,110 ng/mL) had a median time to progression of 11.3 months against more than 30 in the others, an exploratory association. For pembrolizumab, modelling kept exposure within the range giving near-maximal efficacy (sponsor-authored, abstract only).
How the schedule follows from half-life: with first-order elimination each half-life removes half of what remains, so repeated doses build to a steady state where intake per interval equals elimination per interval. In a modelling paper the same total daily dose gives the same average exposure whatever the interval, which changes only the swing; and the terminal half-life can overpredict accumulation (diazepam, simulated: terminal 29.7 h against about 5.3 h operational). The rule that steady state takes about five half-lives is arithmetic plus convention; no primary source opened states it. 161718192021
Reported, not yet replicated
Documented cases where the dose was later judged wrong or contested more
Zolpidem (FDA, 2013): FDA required lower recommended doses for women, the immediate-release dose halved, because in pharmacokinetic trials about 15% of women and 3% of men had blood levels above about 50 ng/mL (a level linked to impaired driving) about 8 hours after the immediate-release dose; label Cmax and AUC are about 45% higher in women. Contested: a 2019 reanalysis argued 8-hour impairment in women was not shown, and prescribing data show lower-dose forms rose 30% after the notice.
Dasatinib: the phase II dose of 70 mg twice daily was compared in a randomised 670-patient phase III with 100 mg once daily; efficacy was similar and pleural effusion was 7% against 16% and grade 3 to 4 thrombocytopenia 22% against 37% (abstract only).
Sotorasib (contested): approved at the higher of two doses with a requirement to compare doses. In a randomised phase 2 (n = 209) response was 32.7% at 960 mg and 24.8% at 240 mg, with median progression-free survival 5.4 against 5.6 months; the study was not powered for formal testing and its authors include sponsor employees. The later regulatory outcome was not confirmed from a primary document.
Older precedent: ICH E4 says drugs have often been initially marketed at what were later recognised as excessive doses, with thiazide diuretics as the example. Across 132 novel oncology drugs approved 2012 to 2022, 43.9% of postmarketing requirements sought more dosing information (a summary by Friends of Cancer Research staff, not combined here with the figures above). 22232425261714
Contested
What is still not covered deep
Not found in a primary source: the origin of 'about five half-lives', any numeric exposure target outside the few drugs above, evidence on whether Project Optimus improved outcomes, and dose-finding outside oncology and healthy-volunteer work (including paediatrics). The FDA 2003, FDA 2005, FDA 2024 and EMA 2017 documents were read for this atlas and not re-opened for this record. This record describes published practice for understanding; it gives no dosing guidance. 163
Our inference
Why a controllable dose matters more
The answer to 'why a controllable dose': ICH E4 states the aim as a dose "beyond which increases would be unlikely to provide added benefit or would produce unacceptable side effects", and that any dose gives "a mixture of desirable and undesirable effects, with no single dose necessarily optimal for all patients". The dose sets the exposure, and exposure sets both effect and harm. 17
Reported, not yet replicated
His question more
He said: "You maybe do dose response. Now you have how potent the compound is, and you're looking for something that you can control the dosage of to get a desired effect, because actually, I'm not sure why." His words, kept as he said them; the sourced answer is in the section above. 27
Amit's hypothesis
Observation
The models give parameters (clearance, volume, half-life, EC50, ke0). Turning them into a dose and schedule is done in steps: a starting dose from animal data (FDA 2005) or the lowest of several estimates (EMA 2017), escalation in patients, then exposure-response work and, since Project Optimus, randomised dosage comparison. 123
Reported, not yet replicated
What is known
What is not
What would settle it
Answered
Date
2026-11-17
Where
concepts/pharmacokinetics-and-pharmacodynamics#how-a-dose-and-schedule-are-chosen
Note
Answered in this record's body and summarised in the PK/PD concept. Residue named in open_questions: the origin of the five-half-lives rule, outcome evidence for Optimus, non-oncology and paediatric dose-finding.
Still open here
- A primary source for the 'about five half-lives' steady-state rule (Rowland and Tozer was not opened).
- Whether dose optimisation under the 2024 FDA guidance improved patient outcomes.
- Dose selection outside oncology and in children.
- The regulatory outcome for sotorasib, checked against FDA documents.
Not yet written: Hypotheses, What is missing, Who works on it.
Linked from
Sources
- US FDA. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. US FDA (2005). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- European Medicines Agency. Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1). European Medicines Agency (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- US FDA. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases (final guidance). US FDA (2024). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Suntharalingam G, et al.. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028 (2006). paper; opened 2026-11-17 all records citing this
- Eastwood D, Findlay L, Poole S, et al.. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161:512-526 (2010). paper; opened 2026-11-17 all records citing this
- Suh HY, Peck CC, Yu KS, et al.. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther (2016). paper; opened 2026-11-17 all records citing this
- Leach MW, Clarke DO, Dudal S, et al.. Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment. Clin Pharmacol Ther (2021). paper; opened 2026-11-17 all records citing this
- Matsumoto M, Polli JR, Swaminathan SK, et al.. Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC). Clin Pharmacol Ther (2024). paper; opened 2026-11-17 all records citing this
- Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm (2016). paper; opened 2026-11-17 all records citing this
- Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009). paper; opened 2026-11-17 all records citing this
- O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics (1990). paper; opened 2026-11-17 all records citing this
- Iasonos A, Wilton AS, Riedel ER, et al.. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials (2008). paper; opened 2026-11-17 all records citing this
- Yuan Y, Hess KR, Hilsenbeck SG, et al.. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res (2016). paper; opened 2026-11-17 all records citing this
- Collins KP, Yin D, Pithavala YK, et al.. Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules. Cancer Chemother Pharmacol (2025). paper; opened 2026-11-17 all records citing this
- Fourie Zirkelbach J, Shah M, Vallejo J, et al.. Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. J Clin Oncol (2022). paper; opened 2026-11-17 all records citing this
- US FDA. Guidance for Industry: Exposure-Response Relationships, Study Design, Data Analysis, and Regulatory Applications. US FDA (2003). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- ICH. ICH E4: Dose-Response Information to Support Drug Registration. ICH (1994). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Boffito M, Back DJ, Flexner C, et al.. Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. Clin Pharmacol Ther (2021). paper; opened 2026-11-17 all records citing this
- Demetri GD, Wang Y, Wehrle E, et al.. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol (2009). paper; opened 2026-11-17 all records citing this
- Freshwater T, Kondic A, Ahamadi M, et al.. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer (2017). paper; opened 2026-11-17 all records citing this
- Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res (2008). paper; opened 2026-11-17 all records citing this
- US FDA. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem. US FDA (2013). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Greenblatt DJ, Harmatz JS, Roth T. Zolpidem and Gender: Are Women Really At Risk?. J Clin Psychopharmacol (2019). paper; opened 2026-11-17 all records citing this
- Kesselheim AS, Donneyong M, Dal Pan GJ, et al.. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf (2017). paper; opened 2026-11-17 all records citing this
- Shah NP, Kantarjian HM, Kim DW, et al.. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol (2008). paper; opened 2026-11-17 all records citing this
- Hochmair MJ, Vermaelen K, Mountzios G, et al.. Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. Eur J Cancer (2024). paper; opened 2026-11-17 all records citing this
- Amit's dictation of 2026-11-17: what the atlas must contain. Kept in the atlas repository; not published.
- Midazolam injection prescribing information, clinical pharmacology. Pfizer Medical Information. regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Greenblatt DJ, Ehrenberg BL, Culm KE, Scavone JM, et al.. Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions. J Clin Pharmacol (2004). paper; opened 2026-11-17 all records citing this
- Kerbrat A, Ferré JC, Fillatre P, et al.. Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. N Engl J Med (2016). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (8)
This record has been changed 8 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Kind
- big-open
- Register
- open-question
- Triage
- answered
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/questions/how-a-dose-and-schedule-are-chosen.json